Bristol-Myers Squibb Company [BMY] stock is down -1.78 while the S&P 500 has fallen -0.19% on Monday, 12/07/20. While at the time of this article, BMY ATR is sitting at 1.40, with the beta value at 0.66. This stock’s volatility for the past week remained at 1.73%, while it was 2.07% for the past 30-day period. BMY has fallen -$1.11 from the previous closing price of $62.31 on volume of 8.97 million shares.
On 7, December 2020, Bristol Myers Squibb Presents Analyses from Pivotal QUAZAR® AML-001 Study of Onureg® (azacitidine tablets; CC-486) in Adults with Acute Myeloid Leukemia in First Remission. According to news published on Yahoo Finance, Analysis showed treatment with Onureg improved overall survival in patients with both measurable residual disease (MRD) positive status and MRD negative status compared to placebo from the time of randomization.
Analyst Birdseye View:
The most recent analyst activity for Bristol-Myers Squibb Company [NYSE:BMY] stock was on November 10, 2020, when it was Resumed with a Mkt perform rating from Bernstein. Before that, on November 16, 2020, Societe Generale Recapitulated a Buy rating and elevated its amount target to $76. On November 06, 2020, Gabelli & Co Downgrade a Hold rating. On October 19, 2020, Guggenheim Upgrade a Buy rating and increased its price target to $70. On September 29, 2020, Berenberg Initiated a Buy rating and increased its price target to $73. On July 28, 2020, Raymond James Initiated an Outperform rating and boosted its amount on this stock to $75. On April 02, 2020, Morgan Stanley Upgrade an Overweight rating and boosted its target amount on this stock to $64. On March 23, 2020, Societe Generale Downgrade a Hold rating and improved its amount target to $50.
In the past 52 weeks of trading, this stock has oscillated between a low of $45.76 and a peak of $68.34. Right now, the middling Wall Street analyst 12-month amount mark is $75.00. At the most recent market close, shares of Bristol-Myers Squibb Company [NYSE:BMY] were valued at $61.20. According to the average price forecast, investors can expect a potential return of 0.95%.
Bristol-Myers Squibb Company [NYSE:BMY] most recently reported quarterly sales of 10.54 billion, which represented growth of 75.50%. This publicly-traded organization’s revenue is $871,500 per employee, while its income is $114,633 per employee. This company’s Gross Margin is currently 71.50%, its Operating Margin is 8.70%, its Pretax Margin is +19.03, and its Net Margin is +13.15. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at 4.17, 10.48, 10.67 and 5.96 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 47.95 and the whole liability to whole assets at 36.58. It shows enduring liability to the whole principal at 44.44 and enduring liability to assets at 0.34 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 60.58 points at 1st support level, the second support level is making up to 59.97. But as of 1st resistance point, this stock is sitting at 62.20 and at 63.21 for 2nd resistance point.
Bristol-Myers Squibb Company [BMY] reported its earnings at $1.63 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at $1.49/share signifying the difference of 0.14 and 9.40% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were $1.63 calling estimates for $1.48/share with the difference of 0.15 depicting the surprise of 10.10%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Bristol-Myers Squibb Company [NYSE:BMY] is 1.70. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.84. Now if looking for a valuation of this stock’s amount to sales ratio it’s 4.20 and it’s amount to book ratio is 2.77.
The most recent insider trade was by von Autenried Paul, EVP, Chief Information Officer, and it was the sale of 3.0 shares on Nov 25. von Autenried Paul, the EVP, Chief Information Officer, completed a sale of 20000.0 shares on Nov 24. On Nov 24, Dubow Adam, SVP,ChiefCompliance&EthicsOff., completed a sale of 900.0 shares.